The Value of Teledermatology Advice for Anti-EGFR-related Skin Toxicity: a Pilot Study (Preprint)

Abstract

UNSTRUCTURED Despite skin toxicity during anti-EGFR therapy occurs frequently and significantly impacts patients’ quality of life, it is often not recognized nor optimally managed. This may lead to unnecessary dose reductions or treatment discontinuations of the cancer treatment. Access to rapid dermatology advice may be limited in hospitals. In this multicenter pilot study, we conclude that teledermatology may add value for both patients and oncologists in the management of treatment-induced skin toxicity. </sec